Drug Search Results
More Filters [+]

FH-2001

Alternative Names: FH-2001, FH 2001, FH2001
Latest Update: None
Latest Update Note: None

Product Description

FH-2001 is a FGFR/VEGFR targeted drug that can reduce the expression level of PD-L1 in tumor cells by down-regulating the cMYC gene. The anti-tumor activity of FH-2001 has been confirmed in preclinical studies. Apart from exerting potent anti-proliferative effect on FGFR-driven tumors, FH-2001 may be able to overcome primary and secondary resistance of conventional immune checkpoint inhibitors or increase the response rate through PD-L1 regulation. (Sourced from: https://aacrjournals.org/cancerres/article/82/12_Supplement/CT527/701629/Abstract-CT527-A-phase-I-open-label-study-of-FGFR)

Mechanisms of Action: PD-L1 Inhibitor,FGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for FH-2001

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title